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Background: Candidiasis is one of the most common opportunistic oral infections that presents different acute 
and chronic clinical presentations with diverse diagnostic and therapeutic approaches. The present study carries 
out a bibliographic review on the therapeutic tools available against oral candidiasis and their usefulness in each 
clinical situation. 
Material and Methods: Recent studies on treatment of oral candidiasis were retrieved from PubMed and Cochrane 
Library.
Results: Nystatin and miconazole are the most commonly used topical antifungal drugs. Both antifungal drugs are 
very effective but need a long time of use to eradicate the infection. The pharmacological presentations of micon-
azole are more comfortable for patients but this drug may interact with other drugs and this fact should be assessed 
before use. Other topical alternatives for oral candidiasis, such as amphotericin B or clotrimazole, are not avail-
able in many countries. Oral fluconazole is effective in treating oral candidiasis that does not respond to topical 
treatment. Other systemic treatment alternatives, oral or intravenous, less used are itraconazole, voriconazole or 
posaconazole. Available novelties include echinocandins (anidulafungin, caspofungin) and isavuconazole. Echi-
nocandins can only be used intravenously. Isavuconazole is available for oral and intravenous use. Other hopeful 
alternatives are new drugs, such as ibrexafungerp, or the use of antibodies, cytokines and antimicrobial peptides. 
Conclusions: Nystatin, miconazole, and fluconazole are very effective for treating oral candidiasis. There are 
systemic alternatives for treating recalcitrant infections, such as the new triazoles, echinocandins, or lipidic pre-
sentations of amphotericin B. 
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Introduction
Oral candidiasis (candidosis) is one of the most com-
mon opportunistic buccal infection that is caused by 
Candida albicans and other species included in the ge-
nus Candida. Candidiasis commonly presents as a mild 
disease of the oral mucous membranes, but sometimes 
can be recalcitrant to treatment or become relapsing or 
recurrent. This oral infection is more frequent in people 
with extreme ages, or suffering from very diverse un-
derlying diseases and, above all, in patients with im-
munodeficiency. Although more than 150 species of 
Candida have been described, 95% of oral candidiasis 
are caused by C. albicans. Other species, such as Can-
dida glabrata, Candida tropicalis, Candida parapsilo-
sis, Candida krusei, Candida dubliniensis or Candida 
guilliermondii can cause infections sporadically often 
complicating the management of these candidiasis (1-5). 
Candida can be part of the human oral microbiota of up 
to 75% of persons without known underlying diseases. 
This colonization occurs from birth and is greatest in 
the extreme ages of life (infants, children and the el-
derly). In adults, colonization is favoured by the use of 
removable dentures, in which biofilms of difficult eradi-
cation are formed, or by the presence of oral alterations, 
such as xerostomia, leucoplakia, lichen, etc. A greater 
colonization can be observed in patients who have re-
ceived antibiotics, corticoids or chemotherapy, or in pa-
tients suffering from diabetes, hospitalized patients and 
people infected by the human immunodeficiency virus 
(HIV). The alteration of the balance between Candida 
and the host due to undesired changes in oral microbiota 
(dysbiosis) or to the damage of anatomical and physico-
chemical barriers facilitates candidiasis. The develop-
ment of candidiasis will depend on both the virulence 
factors of Candida and the clinical conditions of the 
patient (Fig. 1) (1,6-8). Oral candidiasis can be classi-
fied into acute, chronic and Candida-associated lesions, 
such as angular cheilitis, denture stomatitis and medi-
an rhomboid glossitis. Acute candidiasis is dominated 
by pseudomembranous and erythematous candidiasis, 
which may become chronic. Another chronic presenta-
tion is hyperplastic candidiasis (1,4,9). Prevalence and 
incidence of all forms of oral candidiasis have increased 
in recent decades. Candidiasis are observed more fre-
quently in patients of extreme ages, with alterations 
of the skin-mucous barriers by surgical interventions, 
receiving parenteral nutrition, treated with broad-spec-
trum antibiotics or/and corticoids, and presence of neu-
tropenia or immunodeficiency. More than half of people 
who wear removable dentures suffer from oral candi-
diasis. Pseudomembranous oral candidiasis occurs be-
tween 1% and 30% of infant and children and even its 
prevalence is higher in patients with cancer (7-60%) or 
suffering from AIDS (more than 90%) (1,2,6-8,10-12).
Clinical recognition of the oral lesions by the profession-
al is the essential foundation for diagnosis of oral candi-
diasis. This clinical diagnosis of oral candidiasis should 
be confirmed by microscopic observation of Candida in 
the appropriate clinical specimens. Moreover, Candida 
isolation and quantification in pure culture will allow a 
definitive identification. In vitro antifungal susceptibil-
ity testing is an important tool for assessing the best 
Fig. 1. Host predisposing factors and virulence factors of Candida involved in the pathogenesis of oral candidiasis.
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management of patients who have received previous 
antifungal treatments, who suffer relapsing infections 
and when candidiasis are caused by species different to 
C. albicans. However, there are still many controversial 
issues in the microbiological diagnosis particularly in 
denture stomatitis and other Candida-associated lesions 
that need to be solved (9,11,13).
Material and Methods
We searched PubMed limiting the studies in human be-
ings published in English and Spanish from 2010 to the 
date of submission, 2019. The following key words were 
used: “Oral candidiasis” or “oral candidosis” and “an-
tifungal drugs”, “oral candidiasis” or “oral candidosis” 
and “antifungal treatment”, “oral candidiasis” or “oral 
candidosis” and “antifungal therapy”, “oral candidiasis” 
or “oral candidosis” and “polyene”, “oral candidiasis” 
or “oral candidosis” and “nystatin”, “oral candidiasis” 
or “oral candidosis” and “amphotericin B”, “oral can-
didiasis” or “oral candidosis” and “azole”, “oral can-
didiasis” or “oral candidosis” and “miconazole”, “oral 
candidiasis” or “oral candidosis” and “fluconazole”, 
“oral candidiasis” or “oral candidosis” and “clotrima-
zole”, “oral candidiasis” or “oral candidosis” and “isa-
vuconazole”, “oral candidiasis” or “oral candidosis” 
and “itraconazole”, “oral candidiasis” or “oral candi-
dosis” and “posaconazole”, “oral candidiasis” or “oral 
candidosis” and “echinocandins”, “oral candidiasis” or 
“oral candidosis” and “anidulafungin”, “oral candidia-
sis” or “oral candidosis” and “caspofungin”, and “oral 
candidiasis” or “oral candidosis” and “micafungin”. 
We also searched the Cochrane Library (https://www.
cochranelibrary.com). We excluded letters and abstracts 
of meetings.
Results
The bibliographic search identified 296 articles, of 
which 72 were selected after reading the manuscripts 
summaries (Fig. 2). Following the analysis of these ar-
ticles, 33 manuscripts were finally included in the refer-
ences, after excluding those publications that did not fit 
the aims of the present review.
Discussion
Treatment of oral candidiasis is based on three founda-
tions: Early and accurate diagnosis of the type of oral 
candidiasis, correction of the predisposing factors or 
underlying diseases, and the use of the most appropri-
ate antifungal drugs. Promotion of good oral hygiene 
and periodic oral examination, controlling predispos-
ing or facilitating factors, are fundamental to prevent 
infection facilitate treatment if they occur. The choice 
of antifungal drug should take into account the patient 
immune status, the specific characteristics of oral can-
didiasis (clinical presentation, aetiology, susceptibility 
to antifungal drugs, organic location, dissemination) 
and the pharmacological characteristics of the available 
antifungal drugs (administration, metabolism, elimina-
tion, interactions with other drugs and toxicity). Three 
large families group the most commonly used anti-
Fig. 2. Flow diagram showing the key words used in the bibliographic search. Number of studies are indicated in parenthesis.
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fungal drugs: polyenes (amphotericin B and nystatin), 
echinocandins (anidulafungin, caspofungin and mica-
fungin) and azoles. Azoles constitute the most exten-
sive group being divided into imidazoles (clotrimazole, 
Antifungal drugs Species of Candida












Nystatin ●● ●● ●● ●● ●● ●● ●●
Amphotericin B ●● ●● ●● ●● ●● ●● ●●
Miconazole ●● ■ ○ ●● ●● ○ ●● ●
Clotrimazole ●● ■ ●● ●● ○ ●● ●
Fluconazole ●● ■ ○ ●● ●● ○ ■ ○ ●
Isavuconazole ●● ●● ●● ●● ●● ●● ●●
Itraconazole ●● ■ ○ ●● ○ ○ ■ ○ ●
Posaconazole ●● ●● ●● ●● ●● ●● ●●
Voriconazole ●● ● ●● ●● ● ●● ●●
Anidulafungin ●● ●● ● ●● ●● ●● ●●
Caspofungin ●● ●● ● ●● ●● ●● ●●
Micafungin ●● ●● ● ●● ●● ●● ●●
Table 1. In vitro activity of the main antifungal drugs against main Candida species causing oral infection.
Antifungal activity: ●● very active, ● active, ■ variable activity, ○ resistant.
miconazole, ketoconazole, etc.) and triazoles (flucon-
azole, isavuconazole, itraconazole, posaconazole and 
voriconazole) (Tables 1,2). Other drugs with different 
antifungal actions and possible systemic use against su-
 




Amphotericin B lipid 
complex (ABLC)  
Amphotericin B liposomal 
(ABL) 
Clinical efficacy and broad spectrum 
Safe in liver failure 
Activity against fungal biofilms 
Nephrotoxicity* and other adverse 
effects, especially related to infusion 
*Nephrotoxicity is very low using 
ABLC and ABL 
Triazoles 
Fluconazole Clinical efficacy, good safety profile 
and low cost 
It can be combined with other 
antifungals 
Poor activity against C. glabrata and 
null on C. krusei 






1In many countries only available orally 
or not available 
2Low activity against C. tropicalis, C. 
glabrata and C. krusei  
3Drug interactions  
4Need to determine serum concentrations 
in certain situations 
5Intravenous formulation should not be 
used in case of severe renal insufficiency 





Wide spectrum, very good security 
profile 
Use in renal failure and in neutropenia 
Activity against fungal biofilms 
Very low drug interactions 
C. parapsilosis could be less susceptible 
 
	
Table 2. Antifungal drugs available for systemic use in the treatment of oral candidiasis.
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Fig. 3. Fungal targets of current and new antifungal drugs.
perficial mycoses, such as flucytosine, griseofulvin and 
terbinafine, are not used commonly in oral candidiasis 
(7,8,11,14-17). Finally, other therapeutic alternatives 
under development involve the use of new antifungal 
drugs, terpens, probiotics, peptides with antifungal ac-
tivity, sera with polyclonal or monoclonal antibodies or 
cocktails of cytokines (18-25).
The main mechanisms of antifungal action consist in 
the alteration of the membrane or the fungal cell wall by 
inhibition of molecules essential for these, such as er-
gosterol (azoles) or 1,3-ß-D-glucan (echinocandins), or 
by binding to ergosterol (polyenes), causing the forma-
tion of pores and altering the integrity and permeability 
of the cell membrane (Fig. 3). The actions of polyenes 
and echinocandins are usually fungicidal. Conversely, 
azoles are fungistatic for Candida at therapeutic doses 
(7,8,26-28).
Antifungal treatment of oral candidiasis can be carried 
out topically or systemically, usually with oral formula-
tions. Topical drugs are applied to the affected area and 
treat limited infections. Systemic drugs are prescribed 
when the infection is more widespread and has not been 
enough with the topical therapy. Topical antifungals 
have few and mild adverse effects because their absorp-
tion is very limited, and do not interact with other drugs 
the patient may be receiving. The efficacy of topical 
agents in the treatment of oral mycoses depends on the 
type and size of the lesion, the mechanism of action of 
the drug and the characteristics of the formulation, such 
as viscosity, hydrophobicity and acidity. Antifungal 
formulations are marketed as oral suspensions, tablets, 
pastilles, gels, mucoadhesive tablets, toothpastes, etc. 
for facilitating their therapeutic action that are very ef-
fective in curing most oral candidiasis in a few weeks 
(15,17,29).
Although systemic azoles and echinocandins, with bet-
ter tastes and less gastrointestinal adverse reactions, 
have provided new clinical options, topical therapy us-
ing nystatin (polyene) and miconazole (azole) are still 
the main recommended treatments for oral candidiasis 
due to its high efficacy, low cost, and less side effects, 
especially in low-income countries. The accumulated 
experience is important and their usefulness is clearly 
defined (7,8,14-17).
In 2016, the Infectious Diseases Society of America 
(IDSA) updated its clinical practice guidelines for the 
management of candidiasis, including oral candidiasis 
(11). These recommendations include the treatment of 
mild disease with miconazole (muco-adhesive buccal 
50-mg tablet once daily for 7-14 days). Alternatives for 
mild disease include nystatin suspension (100,000 U/
mL, 4-6 ml, four times daily) or pastilles (1-2 pastilles, 
200,000 U each, four times daily for 7-14 days). More-
over, the World Health Organization recommended that 
topical therapy with nystatin suspension or pastilles can 
be an alternative to oral fluconazole for treating oropha-
ryngeal candidiasis in HIV-positive children and adults 
(8).
Nystatin, obtained from Streptomyces noursei, binds to 
the ergosterol of the fungal plasma membrane and forms 
pores that make it more permeable, causing a loss of 
intracellular potassium with a fungicidal effect. More-
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over, nystatin also causes secondary cell damage by au-
tooxidation. The anti-Candida spectrum of nystatin is 
quite broad. The antifungal cut-off point for polyenes in 
the in vitro susceptibility tests is a minimum inhibitory 
concentration (MIC) of 1 μg/ml. Some clinical isolates 
resistant or less susceptible have been described in Can-
dida lusitaniae, Candida rugosa, Candida haemulonii, 
Candida lipolytica, C. guilliermondii, C. krusei and C. 
glabrata. Nystatin is not absorbed orally. Its parenteral 
use is toxic, but clinical trials have been conducted with 
a liposomal formulation that allows its intravenous ad-
ministration. Its undesirable effects include local irrita-
tion, and when administered orally, nausea, vomiting 
and diarrhoea. Nystatin is probably safe during preg-
nancy and breastfeeding. Treatment is effective only if 
nystatin is administered over a sufficient period. How-
ever, the unpleasant taste and this prolonged treatment 
pattern compromise compliance by the patient (11,14).
The meta-analysis of Lyu X et al. (8) showed that ny-
statin suspension and pastilles in combination for two 
weeks achieved a higher clinical and mycological cure 
rates, and using the nystatin pastilles alone might have 
a higher mycological cure rate, when compared with 
using nystatin suspensions alone. Nystatin pastilles at 
a dose of 400,000 IU resulted in a significantly higher 
mycological cure rate than that administrated at a dose 
of 200,000 IU. Furthermore, treatment with nystatin 
pastilles for four weeks seemed to have better clinical 
efficacy than treatment for 2 weeks. Nystatin suspension 
was not a good choice for infants, children, and HIV/
AIDS patients with oral candidiasis, probably because 
of its short-term action on the oral mucosa. Moreover, 
exposure to nystatin at a concentration 0.25 to 1 times 
the MIC value for 30 minutes resulted in a beneficial 
post-antifungal effect, the delay in fungal regrowth that 
persists after a brief exposure to an antifungal agent. 
(8). Encapsulation of nystatin in nanoparticles or the 
inclusion in toothpastes or tissue conditioners exhibit 
properties that enable its in vitro functionality and may 
provide the basis for new successful approaches for the 
treatment of oral candidiasis (20,30,31).
Amphotericin B is other polyene that has been used 
for many years in the treatment of oral candidiasis, but 
at present, it is practically impossible to find topical 
preparations of this antifungal drug in many countries, 
including Spain. IDSA recommends amphotericin B 
deoxycholate oral suspension as alternative for fluco-
nazole-refractory oral candidiasis (11). In these severe 
situations, amphotericin B deoxycholate, the conven-
tional intravenous formulation, and the less nephrotoxic 
formulations of amphotericin B liposomal and ampho-
tericin B lipid complex can be used (26). 
Miconazole and the rest of azoles (imidazoles or tri-
azoles) block the fungal cytochrome P450-dependent 
lanosterol 14-α-demethylase (Erg11p). This action is 
fungistatic, causing an important alteration of the cel-
lular permeability and the inhibition of the growth of 
the fungal cell. Azoles develop their effect more slowly 
than polyenes, but have less toxicity because their ac-
tion against fungal membranes is more selective than 
that of polyenes. Miconazole has a good in vitro anti-
fungal activity against Candida but this activity is low-
er against some isolates of C. glabrata and C. krusei. 
Miconazole can be administered topically, orally or in-
travenously, but these latter two ways are very infre-
quent. It is administered as miconazole buccal tablets, 
miconazole chewing gum, miconazole oral gel, and mi-
conazole lacquer. In some countries, there is an alter-
native presentation of miconazole as one-daily 50-mg 
mucoadhesive buccal tablet (32). Once daily applica-
tion is an advantage over applying nystatin four or five 
times a day to maintain patient compliance. Miconazole 
mucoadhesive tablets exhibited higher salivary concen-
trations and better tolerance for the patient. The recent 
meta-analysis of Zhang LW et al. (15) showed that mi-
conazole was more effective than nystatin for pseudo-
membranous oral candidiasis. Single daily dose regi-
mens of miconazole buccal tablets are useful for poorly 
compliant patients. However, in HIV-infected patients, 
there was no significant difference in the efficacy be-
tween miconazole and other antifungal drugs. There 
was no significant difference between miconazole and 
other antifungals in terms of the relapse rate. Despite 
its good properties, topical use of miconazole can cause 
itching or burning sensation due to local irritation (less 
than 5% of patients). In addition, miconazole has the 
drawback of possible interaction with other drugs, such 
as warfarin because inhibits the enzyme cytochrome 
P450. Hellfritzsch M et al. (33) found evidence support-
ing a clinically relevant drug-drug interaction between 
warfarin and miconazole oral gel. In contrast, these au-
thors did not find any indication of an interaction be-
tween warfarin and nystatin oral solution. 
Other imidazoles for topical use are bifonazole, clotrim-
azole, eberconazole, fenticonazole, flutrimazole, oxi-
conazole, sertaconazole, sulconazole, terconazole, and 
thioconazole, with a broad-spectrum including Staphy-
lococcus epidermidis and other Gram-positive bacteria. 
However, most are not marketed for oral use in many 
countries, including Spain.
Triazoles, such as fluconazole, isavuconazole, itracon-
azole, voriconazole and posaconazole, have a broader 
spectrum and they are used for the systemic treatment 
of many severe mycoses. There are currently oral and 
intravenous formulations but some of them are not 
available in many countries. One of the main disad-
vantages is that inhibit various isoforms of cytochrome 
P450, which causes an inhibition of the metabolism of 
other drugs metabolized by this route, thus increasing 
their plasma concentrations. This occurs with immu-
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nosuppressant drugs (cyclosporine, tacrolimus, siroli-
mus, etc.), oral anticoagulants (warfarin), some statins, 
H1 antihistamines, benzodiazepines, HIV infection, 
protease inhibitors, and calcium channel blockers. In 
addition, other drugs, such as rifampicin, phenytoin, 
carbamazepine, H2 antihistamines, proton pump in-
hibitors and some antacids, when administered together 
with azoles, can reduce plasma concentrations of these. 
They are category C drugs and you have to avoid them 
in pregnancy if there are other alternatives. 
Oral fluconazole (100-200 mg daily for 7-14 days) is 
recommended for treating moderate to severe oral can-
didiasis (11). Chronic suppressive therapy is usually un-
necessary for oral candidiasis. If required for patients 
who have recurrent infection, fluconazole, 100 mg 3 
times weekly, is recommended. Fluconazole has a good 
antifungal activity against most of the species of Can-
dida. For the clinical isolates of albicans, parapsilosis 
and tropicalis, the in vitro susceptibility cut-off point is 
2 μg/ml. In contrast, for isolates of glabrata, an MIC of 
fluconazole less than 32 μg/ml indicates a dose-depen-
dent susceptibility, whereas all isolates of C. krusei are 
considered intrinsically resistant to fluconazole, inde-
pendently of the MIC. Infections caused by isolates of 
Candida glabrata with dose-dependent susceptibility 
to fluconazole can often be treated satisfactorily using 
doses of 800 mg/day or more (11). Fluconazole resis-
tances have been described in some isolates of C. al-
bicans and C. dubliniensis from HIV-infected patients 
with repeated episodes of oropharyngeal candidiasis 
treated with fluconazole. The maximum activity of flu-
conazole against Candida is reached from a value of 
AUC24h/MIC of 25-100. Fluconazole is characterized 
by its excellent bioavailability and low toxicity. The 
incidence of adverse effects with fluconazole is low, 
among which the most frequent are nausea, vomiting, 
headaches, rash, abdominal pain and diarrhoea. Serious 
side effects are very rare.
In fluconazole-refractory disease, itraconazole oral so-
lution (200 mg once daily for up to four weeks) is rec-
ommended. Itraconazole is a first generation lipophilic 
triazole of limited used because of its irregular oral ab-
sorption and its pharmacological interactions. It is ac-
tive against many clinical isolates of C. glabrata and 
C. krusei resistant to fluconazole. In the case of clinical 
isolates of Candida, the in vitro susceptibility cut-off 
point is 0.125 μg/ml. The maximum activity against 
Candida is reached from an AUC24h/MIC index of 25-
100. The oral formulation can cause gastric discomfort. 
There is a transient elevation of transaminases in about 
2% of patients. Neuropathy, hallucinations, cerebellar 
alterations and hypertriglyceridemia have also been ob-
served. It is contraindicated in patients with heart fail-
ure because of its negative inotropic effect. Oude Lashof 
AM et al. (34) compared in one randomized study, the 
efficacy of fluconazole (100 mg/day for 10 days) and 
itraconazole (200 mg/day for 15 days) in cancer pa-
tients with oropharyngeal candidiasis. The fluconazole 
group got a clinical and mycological improvement of 
66% compared to 54% for the group treated with itra-
conazole. Fluconazole had a significantly better clinical 
and mycological cure rate compared with itraconazole. 
Posaconazole suspension (400mg twice daily for three 
days followed by 400mg daily for up to four weeks) is 
an alternative for treating fluconazole-refractory oral 
candidiasis. Posaconazole has a structure similar to that 
of itraconazole and shows one of the widest antifungal 
spectrum of all triazoles. The in vitro susceptibility 
cut-off point is 0.06 μg/ml and the maximum activ-
ity of posaconazole against Candida is reached from 
an AUC24h/MIC index of 25-100 of posaconazole. Its 
binding to plasma proteins is very high (98-99%). The 
most frequent adverse effects are gastrointestinal dis-
comfort, rash, headache and alterations in the electro-
cardiogram (prolongation of the QT segment) (5,11,25). 
Voriconazole is a second-generation triazole developed 
from fluconazole with also a broad antifungal spec-
trum that can be used as alternative for the treatment 
of fluconazole-refractory oral candidiasis. The in vitro 
susceptibility cut-off point is 0.125 μg/ml for the clini-
cal isolates of C. albicans, C. parapsilosis and C. tropi-
calis; however, it has been established at 0.5 μg/ml for 
C. krusei (35). The maximum activity against Candida 
is reached from an AUC24h/MIC index of 25-100. It is 
widely distributed throughout the tissues and organs. Its 
fixation to plasma proteins is 60%. The oral formulation 
can cause gastric discomfort. Transient visual distur-
bances have also been described in one third of patients, 
abnormalities in liver enzymes that sometimes lead to 
suspension of treatment, rash, hallucinations, headache, 
confusion, hypotension and haematological alterations. 
Exceptional cases of clinical hepatitis, cholestasis and 
fulminant hepatic failure have been reported (11,25,36).
Finally, isavuconazole is a new azole, structurally re-
lated to fluconazole and voriconazole, with one of the 
widest antifungal spectrum of all triazoles that presents 
a very high oral absorption not interfered by the pres-
ence of food, gastric pH modifications, or mucositis. Its 
distribution volume is very high, in spite of it is highly 
bound to plasma proteins. The pharmacological inter-
action with other drugs seems to be lower compared to 
other azoles, facilitating the management of these inter-
action, which is probably the most important advantage 
of this antifungal drug (37).
Echinocandins are a family of semisynthetic lipopep-
tides with a highly selective target, the biosynthesis of 
1,3-ß-D-glucan of the fungal wall, by blocking the ac-
tivity of the enzyme beta-glucan synthetase, with fun-
gicidal effect against Candida and few toxic effects for 
human eukaryotic cells. Its use is exclusively intrave-
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nous. The cut-off points of echinocandins are set at a 
MIC of 0.125 μg/ml for C. glabrata (except for mica-
fungin, for which it is 0.06 μg/ml), of 0.25 μg/ml for C. 
albicans, C. krusei and C. tropicalis, and 2 μg/ml for 
C. guilliermondii and C. parapsilosis. The pharmaco-
dynamics indicator that is related to therapeutic success 
in the treatment of candidiasis is Cmax or AUC24h over 
MIC. The maximum activity against Candida would 
be achieved with serum concentrations of the free drug 
four times higher than the MIC (Cmax/MIC ≥ 4) or with 
an AUC24h/MIC value ≥ 20. Among the advantages of 
echinocandins for the treatment of severe and recalci-
trant oral candidiasis are their anti-biofilm activities 
and their prolonged post-antifungal effect. They can be 
first choice drugs for the treatment of severe candidiasis 
in patients with immunodeficiency, the seriously ill and 
those with a high probability of drug interactions. They 
are category C drugs in pregnancy and should be avoid-
ed if there is another therapeutic alternative, as during 
breastfeeding (38,39,40).
There are other pharmacological preparations that have 
antifungal activity and can be used in combination with 
antifungal drugs. These formulations include chlorhex-
idine, povidone iodine, solutions of gentian violet, po-
tassium permanganate, methylene blue or sodium hypo-
sulfite, propylene glycol, selenium sulphide, boric acid, 
and caffeic acid derivatives (17,21). Several investiga-
tional agents are currently under development against 
old targets, such as ergosterol (tetrazoles VT-1129, 
VT-1161, and VT-1598) or 1,3-β-D-glucan (extended 
half-life echinocandin CD101 or ibrexafungerp -SCY-
078-) that may offer advantages over currently available 
drugs. Ibrexafungerp has the advantages of its oral and 
intravenous administration and of being active against 
fluconazole- and echinocandin-resistant oral isolates 
of Candida. Several agents with novel mechanisms 
of action are also under development such as inositol 
acyltransferase AX001, the dihydroorotate dehydroge-
nase inhibitor F901318, and VL-2397. These newer an-
tifungal drugs may be less susceptible to mechanisms 
of antifungal resistance. Each of these investigational 
agents has the potential to improve patient outcomes in 
the treatment of oral candidiasis. (25).
Treatment of oral candidiasis has several tools available 
to be successful. Topical treatments with nystatin or mi-
conazole are effective in most infections and systemic 
treatment with oral fluconazole shows a similar effica-
cy. The treatment must be personalized considering the 
different clinical characteristics of the patient to avoid 
physiological interactions (pregnancy, lactation, etc.) 
or pharmacological (elderly with multiple treatments, 
critical patients, patients with neoplastic pathologies or 
immunodeficiency, etc.). In the face of treatment fail-
ures, recurrent or relapsing infections, we can count on 
new antifungal agents with old and new mechanisms of 
action. Among these drugs, the new triazoles, and echi-
nocandins offer promising alternatives for treatment.
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